Pediapharm Inc. Announces Changes to Board of Directors; Appoints Michael P. Mueller
MONTREAL, QUEBEC–(Marketwired – June 2, 2014) – Pediapharm Inc. (“Pediapharm” or the “Corporation”) (TSX VENTURE:PDP) advises there have been changes to its Board of Directors. Mr. Angelo Botter has resigned as a director of the Company to pursue other matters. The Corporation’s board of directors would like to thank Mr. Botter for his invaluable contribution to the success of Pediapharm since it was founded and wish him well in his future endeavors.
The Corporation is pleased to announce that Michael P. Mueller has agreed to join the Board of Directors. Mr. Mueller is currently the Chairman of Annidis Corporation and a director of several companies including PSP Investments, the Canadian Tire Bank, Magor Communications Corp. and Emily’s House. From 2003 to 2005, he was the President and CEO of MDS Capital Corporation. Mr. Mueller previously held a series of senior executive positions at TD Bank, including Vice Chairman and Global Head of Investment and Corporate Banking. He is a former member of the Board of Directors of the Scarborough Hospital (past Chair), the Scarborough Hospital Foundation, AIM Therapeutics Inc., Biovest Corp. 1, Budco, TM BioScience, MDS Capital Corporation and Canadian Medical Discoveries Funds I and II. Mr. Mueller holds a Bachelor of Science from the University of Western Ontario and an MBA from York University.
“We are very much looking forward to Mr. Mueller’s contributions as he brings tremendous experience not only in the health care sector but also in the small cap investment space. It was also important for us to bring expertise and Board presence across Canada and Mike’s appointment fits perfectly with this objective” said Sylvain Chretien, President and CEO of Pediapharm.
“Pediapharm will greatly benefit from Mr. Mueller’s extensive background and experience. Mike definitely brings a complementary skill set to the existing Board and management team and we are looking forward to his contributions,” commented Mr. Pierre Lapalme, Chairman of Pediapharm.
About Pedipharm Inc.
Pediapharm is the only Canadian specialty pharmaceutical company dedicated to serving the needs of the pediatric community. Its mission is to bring to the Canadian market the latest innovative pediatric products with the objective to improve the health and the well-being of children in Canada. Since its debut in 2008, Pediapharm has entered into numerous commercial agreements with partners from Canada and other countries around the world. The company’s innovative product portfolio includes NYDA®; a breakthrough treatment for head lice; EpiCeram® a non-steroid emulsion for eczema; KoolEffect™ which reduces the symptoms of fever; and VapoLyptus™; a soothing vapour patch of Eucalyptus and Camphor.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
President and Chief Executive Officer
+1-514-762-2626 ext. 201
Chief Financial Officer
+1-514-762-2626 ext. 202
Relations Publiques Paradox Public Relations Inc.